(Q24240891)

Maria Angeles Lopez-Olivo

8

0 references

Elizabeth Tanjong Ghogomu

6

0 references

7

0 references

Jasvinder Singh

Jasvinder A Singh

1

0 references

George Wells

3

George A Wells

0 references

Maria E Suarez-Almazor

4

Maria E Suarez-Almazor

0 references

Robin Christensen

2

Cochrane Database of Systematic Reviews

Robin Christensen

0 references

publication date

15 April 2009

0 references

published in

0 references

cites work

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Evidence that cytokines play a role in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Second-line drug therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

New cytokine targets in inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

T cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Rheumatoid arthritis. Pathophysiology and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Quality of life in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Number needed to treat (NNT): implication in rheumatology clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Utilization of the PICO framework to improve searching PubMed for clinical questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Macrophages and their products in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Disease assessment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

The Mast Cell in Inflammatory Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Work disability in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

7 January 2021

Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

7 January 2021

Tumor necrosis factor inhibitors for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

7 January 2021

Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

7 January 2021

Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

7 January 2021

Epidemiology and burden of illness of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

7 January 2021

Patient-reported outcomes and their role in the assessment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848

7 January 2021